Drug intelligence / Profile preview

HEPA44

Development stage: Unknown
Lead developer: Tasly Biopharmaceuticals
Modality: Peptides, Vaccines & Immunotherapeutics

Overview

HEPA44 is a therapeutic synthetic peptide vaccine developed by Tasly Biopharma for the treatment of chronic Hepatitis B. It is a water-insoluble polypeptide composed of 44 artificially designed linear peptides derived from Hepatitis B virus (HBV) protein sequences. Designed using an epitope-based approach, it incorporates various immune response epitopes from different HBV antigens. Clinical trials in China (Phase I and II) have demonstrated high HBeAg serological conversion rates, a favorable safety profile, and long-term persistence without viral rebound or drug resistance. Tasly Biopharma is currently pursuing an Investigational New Drug (IND) application with the FDA to initiate clinical trials in the United States.

Beyond the preview

Go deeper on HEPA44.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HEPA44.

Explore the full profile